Alnylam Pharmaceuticals, Inc. (ETR:DUL)

Market Cap	39.15B
Revenue (ttm)	2.74B +53.2%
Net Income	37.13M
EPS	0.28
Shares Out	n/a
PE Ratio	1,054.47
Forward PE	33.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7
Average Volume	12
Open	294.40
Previous Close	304.20
Day's Range	294.40 - 294.40
52-Week Range	293.40 - 417.40
Beta	0.44
RSI	35.06
Earnings Date	Feb 20, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: DUL

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD